← 返回

人类 NK 细胞的泛癌单细胞全景图

英文原题:A pan-cancer single-cell panorama of human natural killer cells.

查看英文原题

A pan-cancer single-cell panorama of human natural killer cells.

PubMed 2023/08/21(内容时间) Cell Q1 · IF 45.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞在抗肿瘤进展的先天免疫应答中发挥着不可或缺的作用。为了描绘其在肿瘤微环境中的表型和功能多样性,我们对来自716例癌症患者、涵盖24种癌症类型的NK细胞进行了整合单细胞RNA测序分析。我们观察到NK细胞组成的异质性具有肿瘤类型特异性。值得注意的是,我们鉴定出一组肿瘤相关NK细胞,它们在肿瘤中富集,表现出受损的抗肿瘤功能,并与不良预后和免疫治疗耐药相关。特定的髓系细胞亚群,尤其是LAMP3+树突状细胞,似乎介导了对NK细胞抗肿瘤免疫的调控。我们的研究为基于NK细胞的癌症免疫提供了见解,并突出了NK细胞亚群作为治疗靶点的潜在临床价值。

展开英文摘要原文

Natural killer (NK) cells play indispensable roles in innate immune responses against tumor progression. To depict their phenotypic and functional diversities in the tumor microenvironment, we perform integrative single-cell RNA sequencing analyses on NK cells from 716 patients with cancer, covering 24 cancer types.

We observed heterogeneity in NK cell composition in a tumor-type-specific manner.

Notably, we have identified a group of tumor-associated NK cells that are enriched in tumors, show impaired anti-tumor functions, and are associated with unfavorable prognosis and resistance to immunotherapy. Specific myeloid cell subpopulations, in particular LAMP3 + dendritic cells, appear to mediate the regulation of NK cell anti-tumor immunity.

Our study provides insights into NK-cell-based cancer immunity and highlights potential clinical utilities of NK cell subsets as therapeutic targets.

论文信息

作者
Tang F、Li J、Qi L、Liu D、Bo Y、Qin S、Miao Y、Yu K
第一作者单位
Biomedical Pioneering Innovation Center (BIOPIC), Academy for Advanced Interdisciplinary Studies, School of Life Sciences, Peking University, Beijing 100871, China.China
通讯作者单位
Biomedical Pioneering Innovation Center (BIOPIC), Academy for Advanced Interdisciplinary Studies, School of Life Sciences, Peking University, Beijing 100871, China; Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen 518132, China. Electronic address: zemin@pku.edu.cn.China
文献类型
非美国政府资助研究
期刊
Cell2023 Sep 14
原文标识
PubMed 37607536 · DOI 10.1016/j.cell.2023.07.034